TerrAscend Names New President Of Northeast Region TerrAscend Corp. (OTCQX: TRSSF) has tapped Karim Bouaziz to serve as president of the Northeast region.
September 14, 4:45 PM
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced topline results from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in Class 1 cystic fibrosis (CF) patients with at least one nonsense mutation.
September 13, 5:18 PM
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to GENFIT’s (NASDAQ: GNFT) drug candidate GNS5611 (ezurpimtrostat) for the treatment of cholangiocarcinoma.
September 13, 4:58 PM
Conformis (NASDAQ: CFMS) has received 510(k) clearance from the U.S. Food and Drug Administration for its Actera Hip System. Actera utilizes an advanced tri-taper femur stem design that facilitates direct anterior approach total hip arthroplasties, and provides an additional stem option to orthopedic surgeons.
September 12, 3:01 PM
BioLineRx (NASDAQ: BLRX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate Motixafortide in stem cell mobilization (SCM) for autologous bone marrow transplantation for multiple myeloma patients.
September 9, 6:47 PM
In 2016, Kanye West's apparel brand Yeezy partnered with Adidas AG - ADR (OTCQX: ADDYY) for Adidas + Kanye West to manufacture footwear, apparel and accessories.
September 9, 4:57 PM
The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ: SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.
September 6, 5:11 PM
The European Commission (EC) has expanded the marketing authorization for Rhythm’s (NASDAQ: RYTM) lead drug product IMCIVREE (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age an
Iveric Bio Shares Shoot Higher Following Positive Top-line Data From Late-Stage Geographic Atrophy Study
September 6, 9:58 AM
Iveric Bio (NASDAQ: ISEE) announced positive topline results from the second Phase 3 clinical trial of Zimura (avacincaptad pegol) for the treatment of geographic atrophy (GA).